3/18
02:52 pm
BTAI
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Low
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
3/14
07:24 am
BTAI
Rating for BTAI
Low
Report
Rating for BTAI
2/21
08:00 am
BTAI
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "neutral" rating re-affirmed by analysts at UBS Group AG. They now have a $4.00 price target on the stock, down previously from $9.00.
Medium
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "neutral" rating re-affirmed by analysts at UBS Group AG. They now have a $4.00 price target on the stock, down previously from $9.00.
2/21
07:38 am
BTAI
Rating for BTAI
Medium
Report
Rating for BTAI